



A nonprofit independent licensee of the Blue Cross Blue Shield Association

## Medication Assurance Program

If you are enrolled in a health benefit plan administered by Excellus BlueCross BlueShield where the Medication Assurance Program benefit applies:

The following drugs were preliminarily approved through the accelerated approval pathway by the U.S. Food and Drug Association (FDA). At this time, these drugs have unconfirmed clinical benefit and **will not be covered under prescription drug benefits or medical benefits**. Drug manufacturers of the drugs listed below are required to conduct clinical studies to prove clinical benefit in order to achieve traditional/final FDA approval. These drugs will continue to be monitored and remain uncovered until clinical benefits are proven and confirmed by criteria set forth by the FDA.

- AMONDYS 45\*
- AMTAGVI\*
- ARIKAYCE
- AVMAPKI / FAKZYNJA
- BELEODAQ\*
- BIZENGRI\*
- COLUMVI\*
- DANYELZA\*
- ELREXFIO\*
- EMRELIS\*
- EXONDYS 51\*
- FOLOTYN\*
- FORZINITY
- HERNEXEOS
- IQIRVO
- KEBILIDI\*
- LIVDELZI
- LUNSUMIO\*
- LYNOZYFIC\*
- LYTGOBI
- MODEYSO
- NORTHERA
- OCALIVA
- OJEMDA
- OXBRYTA
- PRALATREXATE\*
- QALSODY\*
- REZDIFRA
- SKYSONA\*
- TALVEY\*
- TAZVERIK
- TECELRA\*
- TECVAYLI\*
- VILTEPSO\*
- VONJO
- VOXZOGO
- VYONDYS 53\*
- ZIIHERA\*
- ZYNLONTA\*

If you have questions regarding your drug coverage, please contact customer care at the number on the back of your card.

\*Medical benefit drug